GB2512314A - Statin composition - Google Patents

Statin composition Download PDF

Info

Publication number
GB2512314A
GB2512314A GB1305439.0A GB201305439A GB2512314A GB 2512314 A GB2512314 A GB 2512314A GB 201305439 A GB201305439 A GB 201305439A GB 2512314 A GB2512314 A GB 2512314A
Authority
GB
United Kingdom
Prior art keywords
vitamin
atorvastatin
folic acid
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1305439.0A
Other versions
GB201305439D0 (en
Inventor
Kartar Singh Lalvani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1305439.0A priority Critical patent/GB2512314A/en
Publication of GB201305439D0 publication Critical patent/GB201305439D0/en
Publication of GB2512314A publication Critical patent/GB2512314A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for the treatment or prophylaxis of mixed dyslipidemia comprises a statin (preferably Atorvastatin), vitamin D, folic acid or folate, vitamin B6 and vitamin B12. The composition may comprise aspirin. The vitamin D may be vitamin D3. The composition may consist essentially of Atorvastatin, vitamin D3, folic acid, vitamin B6 and vitamin B12 in which the weight of vitamin B12 is greater than 100 micrograms. The compositions may also be useful for the treatment or prophylaxis of hyperhomocysteinemia, hypercholesterolemia and/or coronary heart disease. The composition may be synergistic.

Description

DESCRIPTION OF INVENTION
Title: Statin composition
TECHNICAL FIELD
This invention concerns a composition for the treatment orprophylaxis of Mixed Dyslipidemia, Hypercholesterolemia, Hyperhomocysteinemia and Coronary heart disease, that includes Atorvastatin, Vitamin D3, Folic acid, Vitamin B 12, Vitamin B6, and Aspirin.
BACKGROUND ART
Mixed Dyslipidemia Mixed dyslipidemia is the combination of elevated LDL cholesterol and triglyceride and decreased High-density liproprotein (HDL) Cholesterol.
It may often occur with certain genetic disorders such as familial combined hyperlipidemia, familial dysbetalipoproteinemia, which is also known as type Ill hyperlipoproteinemia, diabetes mellitus, a metabolic syndrome, or because of the use of drugs such as immunosuppressive agents or protease inhibitors.
Patients with Mixed dyslipidemia usually have increased numbers of triglyceride-rich remnant lipoproteins, which includes very-low-density lipoprotein (VLDL) remnants and intennediate-density lipoproteins (JDLs), as well as increased numbers of small dense LDL particles. VLDL cholesterol is typically increased in quantity and most VLDL cholesterol is in smaller VLDL remnants.
Flyperhomocysteinemia Homocysteine is a naturally occurring molecule in the body and is required in several reactions that occur within the cells that comprise the human body. The reactions involved result in the formation of cysteine and methionine, which can be further used by the body. If the pathways to either cysteine or methionine are blocked then homocysteine levels may rise.
Three enzymes are associated with elevated levels of homocysteine. These enzymes are methylenetetrahydrofolate reductase (MTHFR), cystathionine beta-synthase (CBS) and methionine synthase (MS).
Methylenetetrahydrofolate reductase (MTHFR) is required to form 5-methyl tetrahydrofolate. This is required in order to convert homocysteine to methionine. If this can not be formed then homocysteine levels will increase.
Methionine synthase (MS) is responsible for the regeneration of methionine from homocysteine.
If homocysteine is not converted to methionine the net result is an increase in homocysteine. The final enzyme associated with elevated homocysteine levels is cystathionine beta-synthase (CBS). This is required in order to convert homocysteine to cysteine. If this enzyme is not present, then homocysteine levels will consequently increase.
Hypercholesterolemia Hypercholesterolemia, or high cholesterol, occurs when there is too much cholesterol in the body. Cholesterol is a soft, waxy, fat-like substance that is a natural component of all the cells of the body.
The body makes all the cholesterol it needs. Any added dietary cholesterol can cause harm.
High cholesterol raises the risk for heart disease, heart attack, and stroke. When there is too much cholesterol circulating in the blood, it can create sticky deposits, called plaque, along the artery walls.
Plaque can eventually narrow or block the flow of blood to the brain, heart, and other organs. Blood cells that get caught on the plaque form clots, which can break loose and completely block blood flow through an artery, causing heart a attack or stroke.
There are two types of cholesterol -HDL (high density lipoproteins) and LDL (low density lipoproteins). The amount of HDL relative to LDL is considered a more important indicator of the risk of heart disease.
Coronary heart disease Coronary heart disease (CHD) is a disease in which a waxy substance called plaque builds up inside the coronary arteries. These arteries supply oxygen-rich blood to the heart muscle. When plaque builds up in the arteries the condition is called atherosclerosis.
The buildup of plaque occurs over many years. Over time plaque can harden or rupture. Hardened plaque narrows the coronary arteries and reduces the flow of oxygen-rich blood to the heart.
If the plaque ruptures, a blood clot can form on its surface. A large blood clot can mostly or completely block blood flow through a coronary artery. Over time, ruptured plaque also hardens and narrows the coronary arteries.
If the flow of oxygen-rich blood to the heart muscle is reduced or blocked, angina or a heart attack can occur. Angina is chest pain or discomfort. It may feel like pressure or squeezing in the chest. The pain also can occur in the shoulders, arms, neck, jaw, or back.
A heart attack occurs if the flow of oxygen-rich blood to a section of heart muscle is cut off. If blood flow isn't restored quickly, the section of heart muscle begins to die. Without quick treatment, a heart attack can lead to serious health problems or death.
Over time, CHD can weaken the heart muscle and lead to heart failure and arrhythmias.
Heart failure is a condition in which the heart can not pump enough blood to meet your body's needs.
Atorvastatin Atot-vastatin, as a type of Stalin, is a medicine that is used in dyslipidaemia and in reducing the chance of a heart attack or stroke in people at risk. Atorvastatin calcium trihydrate reduces the amount of cholesterol and other lipids produced in the body.
In people with high cholesterol it can help to prevent certain heart and circulation events such as a heart attack or stroke. It may also be useful iii reducing the chances of having certain heart and circulation events, such as a heart attack or stroke, in people who have already had them.
People taking Atorvastatin calcium triliydrate usually need to have a low fat diet which may also help to reduce the amount of cholesterol in their blood.
Statins All statins generally work in the same way. They reduce the amount of cholesterol produced by the liver. To compensate for this reduction, the cells of the liver therefore take up bad' cholesterol from the blood. This reduces the amount of cholesterol in the circulation. With less cholesterol in the blood, the risk of fatty deposits forming, which can first narrow and then block the arteries, is also reduced.
There are currently a number of different statins. While they all work in the same way, there are some subtle differences between them. All of them lower the amount of bad' cholesterol in the blood to a varying degree, but some will also increase the amount of good' cholesterol in the blood. Some staSis also keep on working in the body for a longer period of time than others. The method by which statins are broken down by the body also differs.
DISCLOSURE OF INVENTION
The object of the present invention is to develop a synergistic composition for the treatment or prophylaxis of Mixed Dyslipidemia, 1-lypercholesterolemia, Coronary heart disease and Hyperhomocysteincmia, that could surpass the limited biochemical effects of Atorvastatin by acting on a variety of related bioóhemical fimetions.
Atorvastatin can help to reduce the relative risk of cardiovascular events. It can help to reduce 24 hour systolic and diastolic blood pressure in patients with hypertension and hypercholesterolemia, It can also improve arterial stififiess possibly by reducing oxidative stress in hypertensive patients. It improves endothelium dependent vasodilation and decreases C-reactive protein in diabetic patients. It improves lipid profiles in hyperlipidemic patients. It helps patients reach the ATP-Ill and European LDL-C goals. It also reduces Acute coronary events, Stroke and total mortality.
However, the primary limitation of the use of Atorvastatin is that it acts on only one biochemical reaction. Like all staSis, Atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue, which plays a key role in production of cholesterol in the body. HMG-CoA reductase is the rate controlling enzyme of the mevalonate pathway, which is the metabolic pathway that produces cholesterol and other isoprenoids.
The following is the biochemical reaction inhibited by Atorvastatin: Enzymenumber:ECI1.1.88 Accepted name hydroxymethylglutaryl-CoA reductase Reaction: (R)-mevalonate + CoA + 2 NAD = 3-hydroxy-3-methylglutaryl-CoA +2NADII+2F{ A synergistic composition that is acting on all related biochemical processes could clearly surpass the limited biochemical effects of Atorvastatin by making the biochemical, and therefore medical, effects far more widespread.
Due to their biochemical functions, Vitamin B6, Vitamin B12 and Folic acid, when combined, could reduce initima medica thickness in people at risk of cerebral ischemia. They would be able to reduce lipoprotein(a) in people with acute myocardial infarction, and also reduce the risk of ischemic or haemorrhagic stoke and the burden of post stroke depression.
Biochemically, when combined, Folic acid and Vitamin B12 would be able to reduce total cholesterol and insulin resistance and improve both coronary circulation and endothelial dysfunction in metabolic syndrome patients.
They could also decrease asymmetrical dimethylargenine (ADMA) levels, along with decreasing homocysteine levels, in metabolic syndrome patients, suggesting that folic acid has several beneficial effects on cardiovascular diseases risk factors.
It is also important to consider hyperhomocysteinemia, which is an independent risk factor for atherosclerotic disease such as Ischemic heart disease, Stroke and Peripheral vascular disease. Higher homocysteine levels are cytotoxic and found in up to 40% vascular disease patients.
Due to their involvement in homocysteine biochemistry, Vitamin B6, Vitamin B 12 and Folic acid are able to reduce circulating homocysteine levels, and Folic acid can prevent homocysteine induced oxidative stress. Vitamin B6, Vitamin B12 and Folic acid deficiency are associated with raised homocysteine levels.
Folic acid can lower homocysteine levels by increasing the rate of recycling of honiocysteine to methionine, thereby preventing homocysteine induced oxidative stress and consequently endothelial injury.
Vitamin D3 can help to increase Anti-inflammatory cytokines, to decrease parathyroid hormone, to suppress the renin-angiotensin system (WAS), and has vasculoprotective properties. In reducing high cholesterol, Vitamin D3 and Atorvastatin can therefore act synergistically by reducing high cholesterol.
Individually, Vitamin D3 helps to relieve muscle pain and inflammation in hypercholesterolemic patients. Its deficiency is associated with hypertension and hyerlipidemia, thereby making it a potential pathological factor in cardiovascular diseases. * 9
Constituents The constituents of the formulation are: Atorvastatin VitaminD3 Folic acid Vitamin B12 VitaminB6 A possible adthtion to this formulation is Aspirin Vitamin D3 is part of a broader group of substances called Vitamin D of which Vitamin D3 is the most active form. Other forms of Vitamin D can substitute for Vitamin D3 to varying but lesser extents.
Folic acid is part of a broader group of substances called Folates of which Folic acid is the most active form. Other Folates can substitute for Folic Acid to varying but lesser extents.
Atorvastatin is part of a group of substances called Statins. Although Atorvastatin is the primary choice of Statin, other statins can substitute for Atorvastatin to varying but lesser extents.
Optimal dosages The following are the optimal dosages of the constituents used. As these dosages are optimal it is possible to use dosages that are above or below these dosages, but the further the dosage is away from the optimal dosages the less effective they are likely to be 10mg Atorvastatin (higher doses can lead to overdosing and adverse events) 1000 T.U. Vitamin D3 2.5mg Folic acid 200mcg Vitamin B12 20mg Vitamin B6 75mg Aspirin The optimal dosage Vitamin B 12 is particularly high and well above that of normal nutritional needs, which are usually lmcg to 5mcg. The purpose of this is to account for an accumulated metabolic need requiring a much greater quantity that would not be enabled by a normal daily intake.
There is therefore also a provision for the formulation to include in excess of iOOmcg Vitamin B12.
The same principle applies to a lesser extent to the dosage used for Folic acid, which is well above the levels required to satisfy normal requirements.
To a certain extent higher thin normal dosages are used in order to facilitate a more immediate satisfying ofT the requirements.
Broad range of dosages The following are the broad range of dosages that the constituents will preferably come within in order to avoid toxicity at one extreme and insufficient efficacy at the other extreme: 5mg to 100mg Atorvastatin LU. to 10,000 lU. Vitamin D3 0.2mg to 7.5mg Folic acid 2meg to 2000mcg Vitamth Bi 2 1.4mg to 200mg Vitamin B6 30mg to 200mg Aspirin
INDUSTMAL APPLICABILITY
According to this invention, there is a synergistic phannaceutical composition for the treatment or prophylaxis of Mixed Dyslipidemia, Hypercholesteroiemia, Hyperhomocysteinemia and Coronary heart disease, that could surpass the limited biochemical effects of Atorvastatin by acting on a variety of related biochemical functions. In its optimal embodiment the composition consists of 10mg Atorvastatin, 1000 I.U. Vitamin 1)3, 2.5mg Folic acid, 20mg Vitamin B6, 200mcg Vitamin B12, and optionally 75mg Aspirin.

Claims (14)

  1. CLAIMS1. A composition for the treatment or prophylaxis of Mixed dyslipidemia consisting essentially of Atorvastatin, Vitamin D3, Folic acid, Vitamin B6, Vitamin B 12, in which the weight of Vitamin B 12 is greater than 1 O0mcg.
  2. 2. A composition for the treatment of Mixed dyslipidemia comprising Atorvastatin, Vitamin D3, Folic acid, Vitamin B6, and Vitamin B12.
  3. 3. A composition according to Claim 2 in which the. dosages are approximately 10mg Atorvastatin, 1000 I.U.Vitamin D3, 2.5mg Folic acid, 20mg Vitamin B6, and 200mcg Vitamin B12.
  4. 4. A composition according to Claim 2 in which the range of dosages is 5mg to 100mg Atorvastatin, 290 I.U. to 10,000 I.U.Vitamin D3, 0.2mg to 7.5mg Folic acid, 1.4mg to 200mg Vitamin B6, and 2mcg to 2000mcg Vitamin B12.
  5. 5. A composition according to any of claims Ito 4 that also includes Aspirin.
  6. 6. A composition according to any of claims 1 to 4 that also includes 75mg Aspirin.
  7. 7. A composition according to any of claims 1 to 4 that also includes 30mg to 200mg Aspirin.
  8. 8. A composition according to any one of claims 1 to 7 in which Vitamin D is used instead of Vitamin D3.
  9. 9. A composition according to any one of claims Ito 7 in which Folates are used instead of Folic acid.
  10. 10. A composition according to any one of claims 1 to 7 in which Statins are used instead of Atorvastatin.
  11. 11. The use in the manufacture of a medicanwnt using a composition as described in any one of the preceding claims.
  12. 12. A composition according to any one of claims 1 to 11 that is also for the treatment or prophylaxis of Hyperhomocysteinemia.
  13. 13. A composition according to any one of claims 1 to II that is also for the treatment or prophylaxis of Hypercholesterolemia.
  14. 14. A composition according to any one of claims I to 11 that is also for the treatment or prophylaxis of Coronary heart disease.
GB1305439.0A 2013-03-26 2013-03-26 Statin composition Withdrawn GB2512314A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1305439.0A GB2512314A (en) 2013-03-26 2013-03-26 Statin composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1305439.0A GB2512314A (en) 2013-03-26 2013-03-26 Statin composition

Publications (2)

Publication Number Publication Date
GB201305439D0 GB201305439D0 (en) 2013-05-08
GB2512314A true GB2512314A (en) 2014-10-01

Family

ID=48326622

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1305439.0A Withdrawn GB2512314A (en) 2013-03-26 2013-03-26 Statin composition

Country Status (1)

Country Link
GB (1) GB2512314A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662062C1 (en) * 2017-05-25 2018-07-23 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method of lipid-lowering therapy in patients with acute coronary syndrome
US20190111064A1 (en) * 2017-10-18 2019-04-18 Interstice Therapeutics, LLC Statin + vitamin d combination drug and method of use
CN111760031A (en) * 2020-07-20 2020-10-13 首都医科大学附属北京朝阳医院 Statin and vitamin D composition and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214383A1 (en) * 2004-03-29 2005-09-29 William Bubnis Multi-vitamin and mineral nutritional supplements
CN101590234A (en) * 2008-05-30 2009-12-02 北京奥萨医药研究中心有限公司 The composition and use thereof that contains statins and vitamin B group
WO2011088209A2 (en) * 2010-01-13 2011-07-21 Cytochroma Inc. 1-deoxy analogs of vitamin d-related compounds
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214383A1 (en) * 2004-03-29 2005-09-29 William Bubnis Multi-vitamin and mineral nutritional supplements
CN101590234A (en) * 2008-05-30 2009-12-02 北京奥萨医药研究中心有限公司 The composition and use thereof that contains statins and vitamin B group
WO2011088209A2 (en) * 2010-01-13 2011-07-21 Cytochroma Inc. 1-deoxy analogs of vitamin d-related compounds
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Atherochek" [online]. Accessed 11 October 2013. Available from http://www.idruginfo.com/?cat=drug&s=Atherochek&ingredient=Atorvastatin/Folic%20Acid/Methylcobalamin/Vitamin%20B6%20(Pyridoxine) *
"Atherochek-10 from Indoco Rem [Atorvastatin]" [online]. Published 8 February 2011. Accessed 11 October 2013. Available from http://web.archive.org/web/20110208054520/http://www.drugsupdate.com/brand/generic/Atorvastatin/6001 *
"Atorvastatin" [online]. Published 6 March 2013. Accessed 11 October 2013. Available from http://web.archive.org/web/20130306040157/http://en.wikipedia.org/wiki/Atorvastatin *
Audio-Digest Internal Medicine, Volume 58, Issue 34, September 14, 2011, "Treating mixed dyslipidemias", Edwin E. Ferguson, MD. Available online at http://www.audio-digest.org/pages/htmlos/summary.html?sub1=IM5834 *
Clinical pharmacology and therapeutics, vol 85, issue 2, Schwartz J., "Effects of Vitamin D Supplementation in Atorvastatin-Treated Patients: A New Drug Interaction With an Unexpected Consequence". *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662062C1 (en) * 2017-05-25 2018-07-23 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method of lipid-lowering therapy in patients with acute coronary syndrome
US20190111064A1 (en) * 2017-10-18 2019-04-18 Interstice Therapeutics, LLC Statin + vitamin d combination drug and method of use
CN111760031A (en) * 2020-07-20 2020-10-13 首都医科大学附属北京朝阳医院 Statin and vitamin D composition and preparation method and application thereof
CN111760031B (en) * 2020-07-20 2022-07-15 首都医科大学附属北京朝阳医院 Statin and vitamin D composition and preparation method and application thereof

Also Published As

Publication number Publication date
GB201305439D0 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
KR101336756B1 (en) Composition for prevention of recurrence of stroke
US9168308B2 (en) Compositions and methods for nutritional supplementation
JPWO2008088030A1 (en) Composition for preventing or treating diseases related to thrombus or embolism
US11147781B2 (en) Methods for alleviating statin myopathy
RU2501557C2 (en) New application of fatty acid (fatty acids) omega-3
KR20070003995A (en) Compositions with reduced hepatotoxicity
KR20070008451A (en) Method for treating osteoarthritis
GB2512314A (en) Statin composition
WO2022125667A9 (en) Compositions having the ability to promote healthy cholesterol levels
WO2008011178A2 (en) Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
Gotto Jr et al. Lipid-modifying and antiatherosclerotic drugs
Sharma et al. A randomized double blind placebo controlled trial of guatteria gaumeri mother tincture in the management of hyperlipidemia
US11116246B2 (en) Compositions of coenzyme Q10 and methods of use
WO2004080488A2 (en) Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor
JP2006117645A (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE
Hadjibabaie et al. Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients
WO2008139314A1 (en) Compositions and methods for treating joint disorders
JP4896501B2 (en) Pharmaceutical composition having blood free fatty acid lowering action
JP2008530153A (en) Combinations in the treatment of manidipine and statins
Hasegawa Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy
Hamilton‐Craig Managing residual risk in patients receiving statin therapy
KR20070015114A (en) Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
Ashcheulova et al. Dislipidemia: definition, diagnostics and treatment
Stojaković et al. Simvastatin-induced nocturnal leg pain disappears with pravastatin substitution
Whayne Women and cardiovascular disease—Prevention of heart disease

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)